Hengrui Pharmaceutical (600276.SH): Clinical trial of Ruikang trastuzumab for injection approved

Zhitongcaijing · 11/25/2025 09:09

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for injectable Ruikang trastuzumab, agreeing to conduct clinical trials with the single drug in patients with HER2 amplified solid tumors.